Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03012841 · ClinicalTrials.gov registry record · NA
STOP Persistent AF
A NA study of Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions.
- Completed
- Registry status
- NA
- Development phase
- 186
- Enrollment target
- 20
- Study locations
NCT03012841 is a NA study of Atrial Fibrillation that has completed, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 186 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03012841, a NA study of Atrial Fibrillation, has completed, sponsored by Medtronic Cardiac Ablation Solutions.
- COMPLETED
- Registry status
- NA
- Development phase
- 186 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate safety and effectiveness of the Arctic Front Advance™ and Freezor MAX® Cardiac CryoAblation Catheters for the treatment of drug refractory recurrent symptomatic persistent atrial fibrillation (AF).
Conditions Studied
Interventions
- DEVICE Arctic Front Advance Cardiac CryoAblation Catheter
Study Locations (20)
Colorado
- Colorado Heart and Vascular - Lakewood
- Medical Center of the Rockies - Loveland
Florida
- Cardiac Arrhythmia Service - Boca Raton
- Saint Vincent's Medical Center - Jacksonville
Illinois
- Northwestern University - Chicago
- NorthShore University Health System - Evanston
New York
- Icahn School of Medicine at Mount Sinai - New York
- Northwell Health (Lenox Hill Hospital and Staten Island University Hospital) - New York
Washington
- Virginia Mason Medical Center - Seattle
- Swedish Medical Center - Seattle
Arizona
- Banner-University Medical Center Phoenix - Phoenix
Maryland
- The Johns Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2019-08-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03012841
The ClinicalTrials.gov registry entry for NCT03012841 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Arctic Front Advance Cardiac CryoAblation Catheter is the first listed.
NCT03012841 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Colorado, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03012841 about?
NCT03012841 is a clinical study titled "STOP Persistent AF". To demonstrate safety and effectiveness of the Arctic Front Advance™ and Freezor MAX® Cardiac CryoAblation Catheters for the treatment of drug refractory recurrent symptomatic persistent atrial fibrillation (AF).
What is the current status of trial NCT03012841?
This trial is currently completed. It is a NA study. The enrollment target is 186 participants. The study started on 2017-03-02. Estimated completion is 2019-08-13.
What conditions does trial NCT03012841 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT03012841?
The interventions under investigation include: Arctic Front Advance Cardiac CryoAblation Catheter (DEVICE).
Who is sponsoring clinical trial NCT03012841?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03012841 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
-
The CONFORM Pivotal Trial
RECRUITING · NA
-
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.